InvivoGen's COVID-19 animation: SARS-CoV-2 infection and treatment
SARS-CoV-2, the causative agent of COVID-19, has spread rapidly around the world, causing a global pandemic. To this day it remains uncontrolled. SARS-CoV-2 infects host cells, and in the more severe cases, this can cause an unbalanced and excessive pro-inflammatory response. Scientists are exploring numerous ways to treat COVID-19, through the repurposed of approved drugs, as well as, novel therapeutics such as antibodies isolated from recovered patients. Additionally, they are developing a preventive strategy, with ongoing clinical trials for the development of a safe and effective vaccine against SARS-CoV-2, with it crucial in curbing viral spread. Watch our video to learn more.
InvivoGen is developing a collection of high-quality and functionally validated research tools to aid in the global research effort. These products include COVID19-related antibodies, proteins, genes, plasmids, and inhibitors. After viewing the animation, browse the collection below.
InvivoGen offers an expanding set of tools to foster research on SARS-CoV-2 infection and immune responses:
- SARS-CoV-2 Cellular Receptor Genes
- SARS-CoV-2 Structural Genes
- SARS-CoV-2 Spike pseudotyping plasmids NEW
- Anti-SARS-CoV Spike mAbs (clone CR3022)
- Anti-SARS-CoV-2 Spike mAb (clone H4) NEW
- Anti-SARS-CoV-2 Spike mAb (clone B38) NEW
- Anti-SARS-CoV Nucleocapsid mAb (clone CR3018) NEW
- Anti-hIL6R mabs (Tocilizumab)
Viral RdRp Inhibitor
- Remdesivir NEW
JAK/STAT Signaling Inhibitors
Endosomal Acidification Inhibitors
- Bafilomycin A1
InvivoGen’s products are for research use only, and not for clinical or veterinary use.